Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant Patients

OBJECTIVE: We aimed to investigate posttransplant Epstein-Barr virus (EBV) and parvovirus B19 DNA in allogeneic stem cell transplant patients between 2009 and 2010. METHODS: Forty-five adult patients in whom allogeneic stem cell transplantation was performed between April 2009 and November 2010 in t...

Full description

Bibliographic Details
Main Authors: Altay Atalay, Selma Gökahmetoğlu, Süleyman Durmaz, İdris Kandemir, Derya Sağlam, Leylagül Kaynar, Bülent Eser, Mustafa Çetin, Hüseyin Kılıç
Format: Article
Language:English
Published: Galenos Publishing House 2014-05-01
Series:Turkish Journal of Hematology
Subjects:
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-50469
_version_ 1828018660419043328
author Altay Atalay
Selma Gökahmetoğlu
Süleyman Durmaz
İdris Kandemir
Derya Sağlam
Leylagül Kaynar
Bülent Eser
Mustafa Çetin
Hüseyin Kılıç
author_facet Altay Atalay
Selma Gökahmetoğlu
Süleyman Durmaz
İdris Kandemir
Derya Sağlam
Leylagül Kaynar
Bülent Eser
Mustafa Çetin
Hüseyin Kılıç
author_sort Altay Atalay
collection DOAJ
description OBJECTIVE: We aimed to investigate posttransplant Epstein-Barr virus (EBV) and parvovirus B19 DNA in allogeneic stem cell transplant patients between 2009 and 2010. METHODS: Forty-five adult patients in whom allogeneic stem cell transplantation was performed between April 2009 and November 2010 in the Erciyes University Faculty of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, were included in the study. EBV and parvovirus B19 DNA positivity was investigated by using realtime polymerase chain reaction technique in 135 plasma samples obtained after transplantation at between 1 and 6 months. Pretransplant serological markers of EBV and parvovirus B19 were provided from patient files. RESULTS: In 32 (71.1%) of the patients, EBV antibodies in the pretransplantation period were as follows: anti-EBNA-1 IgG (+), VCA IgM (-), and VCA IgG (+). In 2 patients (4.45%), these antibodies were as follows: anti-EBNA-1 IgG (+), VCA IgM (-), and VCA IgG (-). In 1 patient (2.2%), they were as follows: anti-EBNA-1 IgG (-), VCA IgM (-), and VCA IgG (+). EBV serological markers were negative in 2 (2.2%) out of 45 patients before transplantation. There was low DNA positivity (<600 copies/mL) in 4 patients (8.9%), and VCA IgM was negative and VCA IgG was positive in these same 4 patients. In spite of low viral load, there were no symptoms related to EBV, and posttransplant lymphoproliferative disorder (PTLD) did not occur. While in 44 (99.7%) of 45 patients parvovirus B19 IgM was negative and IgG was positive, parvovirus B19 IgM was positive and IgG was negative in 1 (2.3%) patient. Parvovirus B19 DNA was not identified in any of the samples obtained from these 45 patients. CONCLUSION: In this study, EBV and parvovirus B19 DNA were investigated in allogeneic stem cell transplant patients. None of the patients developed PTLD and parvovirus B19 DNA positivity was not detected. However, this issue needs to be further evaluated in prospective, multicenter studies with larger series of patients.
first_indexed 2024-04-10T11:06:57Z
format Article
id doaj.art-c1ee237a0b1445b78dfecdd12d553fd6
institution Directory Open Access Journal
issn 1308-5263
language English
last_indexed 2024-04-10T11:06:57Z
publishDate 2014-05-01
publisher Galenos Publishing House
record_format Article
series Turkish Journal of Hematology
spelling doaj.art-c1ee237a0b1445b78dfecdd12d553fd62023-02-15T16:19:22ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632014-05-0131215516010.4274/tjh.2012.0042TJH-50469Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant PatientsAltay Atalay0Selma Gökahmetoğlu1Süleyman Durmaz2İdris Kandemir3Derya Sağlam4Leylagül Kaynar5Bülent Eser6Mustafa Çetin7Hüseyin Kılıç8Erciyes University Faculty Of Medicine, Department Of Clinical Microbiology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Clinical Microbiology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Clinical Microbiology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Clinical Microbiology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Clinical Microbiology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Hematology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Hematology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Hematology, Kayseri, TurkeyErciyes University Faculty Of Medicine, Department Of Clinical Microbiology, Kayseri, TurkeyOBJECTIVE: We aimed to investigate posttransplant Epstein-Barr virus (EBV) and parvovirus B19 DNA in allogeneic stem cell transplant patients between 2009 and 2010. METHODS: Forty-five adult patients in whom allogeneic stem cell transplantation was performed between April 2009 and November 2010 in the Erciyes University Faculty of Medicine, Department of Internal Medicine, Division of Hematology and Oncology, were included in the study. EBV and parvovirus B19 DNA positivity was investigated by using realtime polymerase chain reaction technique in 135 plasma samples obtained after transplantation at between 1 and 6 months. Pretransplant serological markers of EBV and parvovirus B19 were provided from patient files. RESULTS: In 32 (71.1%) of the patients, EBV antibodies in the pretransplantation period were as follows: anti-EBNA-1 IgG (+), VCA IgM (-), and VCA IgG (+). In 2 patients (4.45%), these antibodies were as follows: anti-EBNA-1 IgG (+), VCA IgM (-), and VCA IgG (-). In 1 patient (2.2%), they were as follows: anti-EBNA-1 IgG (-), VCA IgM (-), and VCA IgG (+). EBV serological markers were negative in 2 (2.2%) out of 45 patients before transplantation. There was low DNA positivity (<600 copies/mL) in 4 patients (8.9%), and VCA IgM was negative and VCA IgG was positive in these same 4 patients. In spite of low viral load, there were no symptoms related to EBV, and posttransplant lymphoproliferative disorder (PTLD) did not occur. While in 44 (99.7%) of 45 patients parvovirus B19 IgM was negative and IgG was positive, parvovirus B19 IgM was positive and IgG was negative in 1 (2.3%) patient. Parvovirus B19 DNA was not identified in any of the samples obtained from these 45 patients. CONCLUSION: In this study, EBV and parvovirus B19 DNA were investigated in allogeneic stem cell transplant patients. None of the patients developed PTLD and parvovirus B19 DNA positivity was not detected. However, this issue needs to be further evaluated in prospective, multicenter studies with larger series of patients.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-50469epstein-barr virusparvovirus b19allogeneic stem cell transplantationreal-time pcr
spellingShingle Altay Atalay
Selma Gökahmetoğlu
Süleyman Durmaz
İdris Kandemir
Derya Sağlam
Leylagül Kaynar
Bülent Eser
Mustafa Çetin
Hüseyin Kılıç
Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant Patients
Turkish Journal of Hematology
epstein-barr virus
parvovirus b19
allogeneic stem cell transplantation
real-time pcr
title Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant Patients
title_full Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant Patients
title_fullStr Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant Patients
title_full_unstemmed Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant Patients
title_short Investigation of Epstein-Barr Virus and Parvovirus B19 DNA in Allogeneic Stem Cell Transplant Patients
title_sort investigation of epstein barr virus and parvovirus b19 dna in allogeneic stem cell transplant patients
topic epstein-barr virus
parvovirus b19
allogeneic stem cell transplantation
real-time pcr
url https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-50469
work_keys_str_mv AT altayatalay investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT selmagokahmetoglu investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT suleymandurmaz investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT idriskandemir investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT deryasaglam investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT leylagulkaynar investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT bulenteser investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT mustafacetin investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients
AT huseyinkılıc investigationofepsteinbarrvirusandparvovirusb19dnainallogeneicstemcelltransplantpatients